Acutaas Chemicals Q2 FY27 Results: Consolidated Net Profit ₹123 Crore on Total Income of ₹442 Crore

Earnings
Speciality chemicals

Blacklitt Research27 October 20263 min read

A coastal industrial complex across a bay, with chemical plant structures, storage tanks and red-and-white stacks along the shoreline. — Licjar Xeymelloz, via Wikimedia Commons (CC0). Illustrative image.

Acutaas Chemicals (NSE: ACUTAAS) reported consolidated total income of ₹442.01 crore and net profit of ₹123.14 crore for the quarter ended 30 Sep 2026, it said in a filing on 27 Oct 2026. Standalone total income was ₹441.09 crore and net profit ₹135.74 crore for the same quarter.

Key highlights

Consolidated

Including its subsidiaries

Total income: ₹442.01 crore, up 39.9% YoY and 33.3% QoQ
Net profit and EPS: ₹123.14 crore, up 71.4% YoY; basic EPS ₹15.29, up 73.4% YoY
Other income: ₹5.10 crore, down 48.2% YoY and up 183.0% QoQ

Standalone

The company on its own, without its subsidiaries

Total income: ₹441.09 crore, up 40.4% YoY and 34.9% QoQ
Net profit and EPS: ₹135.74 crore, up 86.2% YoY; basic EPS ₹16.58, up 86.3% YoY
Other income: ₹8.05 crore, down 10.3% YoY and up 79.7% QoQ

Summary

Consolidated ₹ crore
Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
	442.01	316.03	+39.9%	331.48	+33.3%
Revenue from operations	436.92	306.20	+42.7%	329.67	+32.5%
Other income	5.10	9.84	-48.2%	1.80	+183.0%
	123.14	71.86	+71.4%	74.99	+64.2%
Profit before tax	167.36	96.18	+74.0%	103.91	+61.1%
Finance costs	1.02	0.58	+75.5%	1.14	-11.0%
Depreciation	12.69	8.40	+51.0%	9.82	+29.2%
Tax expense	44.22	24.32	+81.8%	28.92	+52.9%
Net profit margin	27.86%	22.74%	+5.12 pp	22.62%	+5.24 pp
EPS, basic (₹)	15.29	8.82	+73.4%	9.07	+68.6%

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Consolidated net profit grew more slowly than income's rival line, profit before tax: net profit rose 71.4% year on year against 74.0% for profit before tax, while total income rose 39.9%. Revenue from operations, at ₹436.92 crore, rose 42.7%, and it is the bulk of the quarter's income, while other income fell from ₹9.84 crore to ₹5.10 crore.

Tax took ₹44.22 crore, or 26.4% of profit before tax, up 81.8% on the year-earlier ₹24.32 crore. Net profit attributable to owners of the company is shown in the statement as ₹125.17 crore, above the ₹123.14 crore profit for the period, so the difference is a non-controlling interest share that the filing does not explain.

Finance costs were small at ₹1.02 crore, or 0.2% of total income, and depreciation rose 51.0% to ₹12.69 crore. The notes describe Indichem Inc.'s semiconductor materials plant in South Korea as inaugurated on 28 Aug 2026 and under trial runs at 30 Sep 2026; the filing does not give an expected commercial production date.

Standalone ₹ crore
Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ
	441.09	314.16	+40.4%	326.89	+34.9%
Revenue from operations	433.05	305.19	+41.9%	322.41	+34.3%
Other income	8.05	8.97	-10.3%	4.48	+79.7%
	135.74	72.89	+86.2%	75.90	+78.8%
Profit before tax	181.08	97.28	+86.1%	104.02	+74.1%
Finance costs	0.99	0.57	+73.7%	1.12	-11.1%
Depreciation	9.31	7.72	+20.6%	9.02	+3.2%
Tax expense	45.34	24.39	+85.9%	28.12	+61.3%
Net profit margin	30.77%	23.20%	+7.57 pp	23.22%	+7.55 pp
EPS, basic (₹)	16.58	8.90	+86.3%	9.27	+78.9%

Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

Standalone net profit rose 86.2% year on year, faster than total income (up 40.4%) and profit before tax (up 86.1%). Revenue from operations rose 41.9% to ₹433.05 crore, while other income fell 10.3% to ₹8.05 crore, equal to 1.8% of total income.

Tax expense of ₹45.34 crore is 25.0% of profit before tax of ₹181.08 crore, compared with 24.39 crore a year earlier. Standalone profit is higher than consolidated profit by ₹12.60 crore, a gap the filing does not break down.

Standalone depreciation rose 20.6% to ₹9.31 crore, and finance costs were ₹0.99 crore. The company operates in a single segment, custom synthesis and manufacturing of speciality chemicals for pharmaceutical APIs and others, so the results carry no separate segment split.

Inference

The auditors' limited review reports on both standalone and consolidated results carry no modification. The board approved the results on 27 Oct 2026.

The filing records a dividend paid of ₹20.47 crore in the half year, including tax, and standalone shareholders' equity of ₹1,864.82 crore at 30 Sep 2026. The filing does not say the reason for the year-on-year growth in revenue and profit, nor the reason for the fair value loss on investments of ₹25.02 crore in the half-year cash flow statement.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.